| Issue |
Section |
Title |
File |
| Vol 92, No 12 (2020) |
Articles |
Clinical and economic comparison of utilization of reslizumab, mepolizumab and benralizumab in the treatment of severe eosinophilic asthma |
(Rus)
|
| Vol 93, No 11 (2021) |
Original articles |
Criteria for the optimal use of interleukin-6 receptor blockers in patients with COVID-19 |
(Rus)
|
| Vol 94, No 3 (2022) |
Original articles |
Analysis of predictors of response to anti-IgE therapy in patients with severe atopic bronchial asthma in real clinical practice |
(Rus)
|
| Vol 94, No 4 (2022) |
Original articles |
Problems and opportunities to improve diagnosis of asthma and chronic obstructive pulmonary disease in Russia: resolution of advisory board |
(Rus)
|
| Vol 94, No 5 (2022) |
Original articles |
Levilimab and baricitinib prescribing experience in outpatient COVID-19 patients’ treatment |
(Rus)
|
| Vol 94, No 5 (2022) |
Original articles |
Efficacy and safety of regdanvimab in patients with mild/moderate COVID-19 and high risk of progression of the disease: a retrospective study in a short-term stay unit |
(Rus)
|
| Vol 94, No 11 (2022) |
Original articles |
The informative value of CD3+CD4+ and CD3+CD8+ T-cell count and cHIS scale as predictors of severe COVID-19 when using interleukin-6 receptor blockers in the in-hospital setting |
(Rus)
|
| Vol 95, No 1 (2023) |
Original articles |
Pre-exposure prophylaxis of new COVID-19 coronavirus infection with tixagevimab/cilgavimab in adult Moscow patients with primary immunodeficiencies |
(Rus)
|
| Vol 95, No 6 (2023) |
Original articles |
Use of a combination of the virus-neutralizing monoclonal antibodies casirivimab and imdevimab for mild to moderate COVID-19 in patients at high risk of progression: Results of the non-interventional observational study |
(Rus)
|
| Vol 95, No 7 (2023) |
Original articles |
Efficacy of dupilumab in real practice in the treatment of severe forms of asthma and atopic dermatitis (comparative retrospective study) |
(Rus)
|
| Vol 95, No 8 (2023) |
Consensuns |
The burden of COVID-19 in a heterogeneous population of immunocompromised patients – realities of the postpandemic |
(Rus)
|
